JP Morgan Chase’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

JP Morgan Chase’s Portfolio ANAC Stock Details ANAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-307,192	Closed	-$16.4M	–	5275
2016 Q1	$16.4M	Sell	307,192 -19,370	-6%	-$1.43M	﹤0.01%	1463
2015 Q4	$36.9M	Buy	326,562 +114,245	+54%	+$12.6M	0.01%	965
2015 Q3	$25M	Buy	212,317 +53,549	+34%	+$6.99M	0.01%	1131
2015 Q2	$12.3M	Buy	158,768 +120,169	+311%	+$7.88M	﹤0.01%	1769
2015 Q1	$2.23M	Buy	38,599 +30,169	+358%	+$1.28M	﹤0.01%	2812
2014 Q4	$272K	Buy	+8,430	New	+$253K	﹤0.01%	3913

Other funds holding ANAC

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

JP Morgan Chase's ANAC Position: Q2 2016 in Review

JP Morgan Chase sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 307,192 shares — an estimated $16.4M sold.

JP Morgan Chase first reported a position in ANAC in Q4 2014 and held it in 6 quarters. The position peaked at $36.9M in Q4 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

JP Morgan Chase reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
JP Morgan Chase sold 307,192 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $16.4M.
JP Morgan Chase first reported a position in ANACOR PHARMACEUTICALS INC COM in Q4 2014 and held it in 6 quarters.
JP Morgan Chase's ANACOR PHARMACEUTICALS INC COM position peaked at $36.9M in Q4 2015.
2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on JP Morgan Chase's 13F filing for Q2 2016, filed 8 Aug 2016.